749 related articles for article (PubMed ID: 30368665)
1. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
2. Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique.
Zigeuner R; Droschl N; Tauber V; Rehak P; Langner C
Urology; 2006 Sep; 68(3):518-22. PubMed ID: 16979727
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
4. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.
Abou Youssif T; Fahmy MA; Koumakpayi IH; Ayala F; Al Marzooqi S; Chen G; Tamboli P; Squire J; Tanguay S; Sircar K
Cancer; 2011 Jan; 117(2):290-300. PubMed ID: 20830770
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
6. Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis.
Rausch S; Beermann J; Scharpf M; Hennenlotter J; Fend F; Stenzl A; Schollenberger D; Bedke J; Kruck S
World J Urol; 2016 Dec; 34(12):1635-1641. PubMed ID: 26995391
[TBL] [Abstract][Full Text] [Related]
7. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
8. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Med Oncol; 2014 Jan; 31(1):792. PubMed ID: 24307346
[TBL] [Abstract][Full Text] [Related]
9. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
10. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
Kim SH; Park WS; Park EY; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
PLoS One; 2017; 12(6):e0179610. PubMed ID: 28654655
[TBL] [Abstract][Full Text] [Related]
14. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.
Kruck S; Bedke J; Hennenlotter J; Ohneseit PA; Kuehs U; Senger E; Sievert KD; Stenzl A
Oncol Rep; 2010 Jan; 23(1):159-63. PubMed ID: 19956876
[TBL] [Abstract][Full Text] [Related]
15. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
17. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
18. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
20. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma.
Rogenhofer S; Kahl P; Mertens C; Hauser S; Hartmann W; Büttner R; Müller SC; von Ruecker A; Ellinger J
BJU Int; 2012 Feb; 109(3):459-65. PubMed ID: 21810159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
